Insulet (Nasdaq:PODD) announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system. The Acton, Massachusetts–based company said the updates to its tubeless, wearable automated insulin delivery patch pump’s algorithm include a new benchmark in tubeless diabetes technology with a lower, 100 mg/dL target glucose option. It also delivers a […]
Featured
Insulet makes Omnipod 5 available with Dexcom G7 15 Day CGM
Insulet (Nasdaq:PODD) today announced immediate compatibility between its Omnipod 5 system and the Dexcom (Nasdaq:DXCM) G7 15 Day CGM. Acton, Massachusetts-based Insulet, which has paired its pumps with previous versions of Dexcom continuous glucose monitors (CGMs), has offered Omnipod 5 with the initial version of G7 since early 2024. However, Dexcom received FDA clearance for people […]
Medtronic begins full commercial rollout of MiniMed 780G with Instinct sensor made by Abbott
Medtronic (NYSE:MDT) today announced the full U.S. launch for its Instinct sensor, made by Abbott, paired with the MiniMed 780G pump. The medtech giant’s diabetes unit — one of the largest diabetes tech businesses in the world — won FDA clearance for its SmartGuard algorithm as an interoperable automated glycemic controller (iAGC) earlier this year, enabling […]
Embecta Q4 sales fall short amid dynamic market, China hurdles
Embecta (Nasdaq:EMBC) today posted fourth-quarter financial results that proved mixed compared to the consensus forecast on Wall Street. Shares of EMBC remained unmoved at $14.64 apiece in pre-market trading today. The Parsippany, New Jersey-based BD Diabetes spinoff reported profits of $26.4 million. That equals 45¢ per share on sales of $264 million for the three […]
PreEvnt brings non-invasive glucose alert device to clinical trials
PreEvnt announced today that its Isaac non-invasive glucose monitoring system has entered clinical trials. Under the direction of Dr. Mangilal Agarwal, the device entered trials at Indiana University, Indianapolis. The study marks a step forward in validating Isaac’s potential as a tool for managing diabetes through breath-based measurements. The current phase of research includes adolescents […]
Abbott initiates correction for FreeStyle Libre 3, Libre 3 Plus CGMs after reports of deaths
Abbott (NYSE:ABT) announced today that it issued a medical device correction for certain FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. This correction comes as a result of an issue that led to hundreds of severe adverse events, including seven deaths. Abbott — one of the largest diabetes tech companies in the world — […]
Insulet CEO Ashley McEvoy lays out plans for Omnipod 6, innovation roadmap
Insulet (Nasdaq:PODD) today hosted its Investor Day, led by President and CEO Ashley McEvoy, laying out the future for the insulin pump maker. McEvoy, who assumed the corner office six months ago, has recently spoken about the company’s use of artificial intelligence to advance its automated insulin delivery (AID) offerings, while competition continues to heat […]
Insulet to launch next-gen Omnipod 6 in 2027, outlines plans for fully closed loop pump for type 2
Insulet (Nasdaq:PODD) today revealed plans for its innovation pipeline, which includes the next-generation Omnipod 6 system. At the company’s Investor Day event, held at its Acton, Massachusetts headquarters, President and CEO Ashley McEvoy laid out the company’s innovation roadmap. That includes updates to the current-generation Omnipod 5 platform, the new Omnipod 6 and a new, […]
Dexcom to launch G7 15 Day CGM next month
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month. The San Diego–based company plans to make the CGM available for people over the age of 18 with diabetes on Dec. 1. Initially, the company plans to make the sensor available for users […]
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer. The continuous glucose monitor (CGM)-based offering received clearance for adults with type 2 diabetes on glargine U-100 long-acting insulin therapy. San Diego-based Dexcom says it marks the first and only CGM-integrated basal dosing optimizer cleared for type 2 diabetes. […]
